MDxHealth SA (MDXH): Price and Financial Metrics
MDXH Price/Volume Stats
| Current price | $2.81 | 52-week high | $8.51 |
| Prev. close | $2.83 | 52-week low | $2.47 |
| Day low | $2.81 | Volume | 6,366 |
| Day high | $2.85 | Avg. volume | 173,540 |
| 50-day MA | $3.37 | Dividend yield | N/A |
| 200-day MA | $4.20 | Market Cap | 75.98M |
MDXH Stock Price Chart Interactive Chart >
MDxHealth SA (MDXH) Company Bio
MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest MDXH News From Around the Web
Below are the latest news stories about MDXHEALTH SA that investors may wish to consider to help them evaluate MDXH as an investment opportunity.
MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue EstimatesMDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 6.25% and 10.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
MDxHealth Reports Q2 and Half Year 2023 ResultsNEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q2 and Half Year 2023 Results Year-over-year Q2 revenues increase by 143% to $16.7 million; excluding GPS, revenues up 29% Q2 gross margin expanded to 59.7% up from 42.4% in the prior year periodAmended GPS purchase agreement with Exact Sciences defers Company’s earn-out payment period from 2024-2026 to now 2025-2027Company reaffirms full year 2023 revenue guidance of $65-70 million IRVINE, CA, and HERST |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning! |
Cano Health, Inc. (CANO) Reports Q2 Loss, Lags Revenue EstimatesCano Health, Inc. (CANO) delivered earnings and revenue surprises of -211.11% and 8.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23NEWS RELEASE10 AUGUST 2023, 4PM ET / 22:00 CET MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23 Company to Host Conference Call with Live Q&A, August 23, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 10, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and half year ended June 30, 2023, after market close |
MDXH Price Returns
| 1-mo | -21.29% |
| 3-mo | -16.62% |
| 6-mo | -1.40% |
| 1-year | -60.20% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -57.49% |
| 2022 | -30.57% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...